DO YOU HAVE

IgA Nephropathy?

Discover if the RUBY-3 clinical study is an option for you!

RUBY-3 is being conducted to determine if a novel investigational drug, povetacicept, is safe and potentially beneficial for people with IgA nephropathy (IgAN). Povetacicept is designed to reduce the inflammation and harmful antibodies that damage the kidneys in patients with IgAN, reducing or possibly reversing kidney damage.

To participate in RUBY-3 you must:

- \rightarrow Be at least 18 years of age
- → Have IgAN that is confirmed by a biopsy
- Currently have active IgAN despite receiving standard treatment(s)

Our study team can answer any questions you may have and help determine if you meet the additional requirements to qualify. All participants receive povetacicept provided at no cost, and reimbursement is available for study-related expenses such as travel.

more information about RUBY-3, contact:	
dy Center:	
ntact Person:	
dress:	
ephone:	
ail:	

Contacting us does not mean that you must join the study or guarantee that you will be able to participate.



DO YOU HAVE

Lupus-Related Kidney Disease (Lupus Nephritis)?

Discover if the RUBY-3 clinical study is an option for you!


RUBY-3 is being conducted to determine if a novel investigational drug, povetacicept, is safe and potentially beneficial for people with lupus nephritis. Povetacicept is designed to reduce the inflammation and harmful antibodies that damage the kidneys in patients with lupus nephritis, reducing or possibly reversing kidney damage.

To participate in RUBY-3 you must:

- \rightarrow Be at least 18 years of age
- > Have lupus nephritis that is confirmed by a biopsy
- Currently have active lupus nephritis despite receiving standard treatment(s)

Our study team can answer any questions you may have and help determine if you meet the additional requirements to qualify. All participants receive povetacicept provided at no cost, and reimbursement is available for study-related expenses such as travel.

For more information about RUBY-3, c	contact:	
Study Center:		
Contact Person:		
Address:		
Telephone:		
Email:		





DO YOU HAVE

Primary Membranous Nephropathy?

Discover if the RUBY-3 clinical study is an option for you!

RUBY-3 is being conducted to determine if a novel investigational drug, povetacicept, is safe and potentially beneficial for people with primary membranous nephropathy. Povetacicept is designed to reduce the inflammation and harmful antibodies that damage the kidneys in patients with membranous nephropathy, reducing or possibly reversing kidney damage.

To participate in RUBY-3 you must:

- \rightarrow Be at least 18 years of age
- Have primary membranous nephropathy that is confirmed by a biopsy
- Currently have active membranous nephropathy despite receiving standard treatments

Our study team can answer any questions you may have and help determine if you meet the additional requirements to qualify. All participants receive povetacicept provided at no cost, and reimbursement is available for study-related expenses such as travel.

or more information about RUBY-3, contact:
tudy Center:
contact Person:
ddress:
elephone:
mail:

Contacting us does not mean that you must join the study or guarantee that you will be able to participate.

